- Trial Phase
- Approved (marketed); ongoing Phase 2/3 studies
- Time to Market
- Already approved and commercially marketed (US and other regions, approved since 2022; earlier-line use since 2024); ongoing trials support further expansion.
- Why 3/10
- No hard, dated binary (PDUFA, advisory committee, or pivotal readout) for CARVYKTI is scheduled in the next ~12 months per available data — the drug is already approved and commercializing — and at JNJ it is one growth driver inside a company guiding to ~$101B of 2026 sales, so the next year is about quarterly net-trade-sales growth, not a binary event; hence a 3, not higher.
For JNJ holders, CARVYKTI is a slow-burn growth contributor — watch the quarterly net-trade-sales updates and any early-line label moves, but don't expect a stock-moving binary.
Price Chart
Executive Summary
CARVYKTI (ciltacabtagene autoleucel / cilta-cel) is an approved, marketed CAR-T cell therapy for multiple myeloma, developed and co-commercialized by Johnson & Johnson's Janssen unit (JNJ) and Legend Biotech (LEGN), where it is essentially Legend's entire business. Net trade sales are growing ~50-62% year over year — about $657M in Q2 2026 and $1.9B for full-year 2025 — with durable efficacy (30-month OS >85% among CARTITUDE-4 responders) and expansion to 18 countries and 10,000+ patients treated. For JNJ it is a meaningful but non-binary growth driver inside a ~$101B guided revenue base; the bull/bear question for the stock is commercial momentum and competition, not a pending approval decision.
How It Works
A one-time "living drug" cell therapy: a patient's own immune cells (T cells) are collected, genetically reprogrammed to recognize a protein called BCMA that sits on myeloma cancer cells, multiplied, and infused back into the patient, where they hunt and kill the cancer. It's a personalized treatment requiring specialized manufacturing, not a standard pill or infusion.
Trial Status
Marketed drug; the pivotal CARTITUDE-4 program continues to generate follow-up data (ASCO 2026: 30-month overall survival >85% among responders), and an active-not-recruiting Phase 2 combination study of cilta-cel plus talquetamab in high-risk multiple myeloma (NCT06550895) is sponsored by Janssen Research & Development with JNJ as affected ticker.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 CARVYKTI net-trade-sales update (Legend/JNJ earnings, expected Q3-Q4 2026)
- Further CARTITUDE-4 / earlier-line follow-up data at major hematology congresses
- Appointment of a permanent Legend Biotech CEO (search underway since July 2026)
- Any label-expansion or new-market (e.g., China) regulatory milestones — none currently dated in available data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
JOHNSON & JOHNSON 8-K JNJ ·Originating report